Effect of non-nucleoside reverse transcriptase inhibitors and protease inhibitors on serum levels of myeloperoxidase and C-reactive protein in HIV-infected individuals
DOI:
https://doi.org/10.1590/s2175-97902020000118780%20Keywords:
MPO, Hs-CRP, IInflammatory, Cardiovascular risk, HIV-infected, Drug classAbstract
It remains unclear whether increased inflammatory and cardiovascular risk biomarkers differ depending on the class of antiretroviral that is used. This study evaluated the plasma levels of inflammatory and cardiovascular risk biomarkers, such as MPO, hs-CRP, glucose, lipid profile, ALT (GPT), AST (GOT), urea and creatinine, as well as the blood count, of all the 164 participants in the study, either infected or un-infected with HIV. Thirty of the 104 HIV-infected individuals did not receive any antiretroviral; twenty-four of them were treated with non-nucleoside reverse transcriptase inhibitor class; and fifty took protease inhibitors. The control group consisted of sixty non-HIV infected individuals. In the case of the HIV-infected volunteers, the CD4+ T lymphocyte counts and viral load were also analyzed. Regardless of the hematological and biochemical changes resulting from the antiretroviral therapy (ART), the MPO and hs-CRP values significantly increased for the HIV-infected individuals (treated or untreated), irrespective of the class of ART that was used. This is important because these biomarkers are designed to be predictors of the risk of cardiovascular disease. The results of this study provide supporting evidence for the hypothesis that HIV-infected individuals are at increased risk of developing cardiovascular disease related to chronic inflammations, despite virological control with ART, and regardless of the class of ART that is used.
Downloads
References
Baker J V, Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS. 2010;5(6): 511-516.
Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108(2):1440-1445.
Ballocca F, D’Ascenzo F, Gili S, Grosso Marra W, Gaita F. Cardiovascular disease in patients with HIV. Trends Cardiovasc Med. 2017;27(8):558-563.
Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;23(3):236-245.
Borato DCK, Parabocz GC, Ribas SRW, Kalva-Filho CA, Borba LM, Ito CAS, et al. Changes of metabolic and inflammatory markers in HIV infection: Glucose, lipids, serum Hs-CRP and myeloperoxidase. Metabolism. 2012;61(10):1353-1360.
Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179-1184.
Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: Epidemiology, pathogenesis, and clinical management. AIDS. 2010;24(6):789-802.
Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881-1883.
Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation . 2008;118(2):e29-35.
Dubé MP. Disorders of Glucose Metabolism in Patients Infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;31(6):1467-1475.
Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, et al. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis. 2004;39(2):248-255.
Hresko RC, Kraft TE, Tzekov A, Wildman SA, Hruz PW. Isoform-selective inhibition of facilitative glucose transporters: Elucidation of the molecular mechanism of HIV protease inhibitor binding. J Biol Chem. 2014;289(23): 16100-16113.
Hruz PW. Molecular mechanisms for insulin resistance in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 2011;25(3):459-468. doi:10.1016/j.beem.2010.10.017.
» https://doi.org/10.1016/j.beem.2010.10.017
Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205(S3):75-82.
Karakas M, Koenig W. Myeloperoxidase Production by Macrophage and Risk of Atherosclerosis. Curr Atheroscler Rep. 2012;14(3):277-283.
Kristoffersen US, Kofoed K, Kronborg G, Benfield T, Kjaer A, Lebech AM. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIV Med. 2009;10(10):627-633.
Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS . 1999;13(7):805-810.
Martínez E, García-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis . 2000;31(5):1266-1273.
Meuwese MC, Stroes ESG, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals. The EPIC- Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50(2):159-165.
Neuhaus J, Jacobs, Jr DR, Baker J V., Calmy A, Duprez D, La Rosa A, et al. Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection. J Infect Dis . 2010;201(12):1788-1795.
Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009;50:S346-51.
Pereira SA, Branco T, Côrte-Real RM, Germano I, Lampreia F, Caixas U, et al. Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV- infected patients. Br J Clin Pharmacol. 2006;61(5):601-604.
Reyskens KMSE, Essop MF. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system. Biochim Biophys Acta. 2014;1842(2):256-268.
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation . 2003;107(3):363-369.
Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199:79-86.
Ross AC, Rizk N, O’Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima-Media Thickness in HIV-Infected Patients Receiving Antiretroviral Therapy. Clin Infect Dis . 2009;49(7):1119-1127.
Schindhelm RK, Van Der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: A useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009;55(8):1462-1470.
Semba RD, Shah N, Vlahov D. Risk factors and cumulative incidence of anaemia among HIV-infected injection drug users. Int J STD AIDS . 2002;13(2):119-123.
Sloand E. Hematologic complications of HIV infection. AIDS Rev 2005;7(4):187-196.
Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep. 2017;22(2):51-73.
Van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1(1):064-74.
Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies. Clin Infect Dis . 2004;38(10):1454-1463.
Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346(26): 2039-2046.
World Health Organization. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: World Health Organization; 2011, 1-6 p.
Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol. 2009;53(3):317-333.
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
